Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 749

1.

Epidemiology and biology of relapse after stem cell transplantation.

Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N.

Bone Marrow Transplant. 2018 Apr 18. doi: 10.1038/s41409-018-0171-z. [Epub ahead of print] Review. No abstract available.

PMID:
29670211
2.

Precision antimicrobial therapeutics: the path of least resistance?

Spaulding CN, Klein RD, Schreiber HL 4th, Janetka JW, Hultgren SJ.

NPJ Biofilms Microbiomes. 2018 Feb 27;4:4. doi: 10.1038/s41522-018-0048-3. eCollection 2018. Review.

3.

Functional role of the type 1 pilus rod structure in mediating host-pathogen interactions.

Spaulding CN, Schreiber HL 4th, Zheng W, Dodson KW, Hazen JE, Conover MS, Wang F, Svenmarker P, Luna-Rico A, Francetic O, Andersson M, Hultgren S, Egelman EH.

Elife. 2018 Jan 18;7. pii: e31662. doi: 10.7554/eLife.31662.

4.

Narrowing the spectrum: the new frontier of precision antimicrobials.

Paharik AE, Schreiber HL 4th, Spaulding CN, Dodson KW, Hultgren SJ.

Genome Med. 2017 Dec 14;9(1):110. doi: 10.1186/s13073-017-0504-3.

5.

Catheterization alters bladder ecology to potentiate Staphylococcus aureus infection of the urinary tract.

Walker JN, Flores-Mireles AL, Pinkner CL, Schreiber HL 4th, Joens MS, Park AM, Potretzke AM, Bauman TM, Pinkner JS, Fitzpatrick JAJ, Desai A, Caparon MG, Hultgren SJ.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8721-E8730. doi: 10.1073/pnas.1707572114. Epub 2017 Sep 25.

6.

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.

Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ.

Nature. 2017 Jun 22;546(7659):528-532. doi: 10.1038/nature22972. Epub 2017 Jun 14.

7.

Combined Analysis of Extant Rhynchonellida (Brachiopoda) using Morphological and Molecular Data.

Bapst DW, Schreiber HA, Carlson SJ.

Syst Biol. 2018 Jan 1;67(1):32-48. doi: 10.1093/sysbio/syx049.

8.

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T.

Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26.

9.

Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections.

Schreiber HL 4th, Conover MS, Chou WC, Hibbing ME, Manson AL, Dodson KW, Hannan TJ, Roberts PL, Stapleton AE, Hooton TM, Livny J, Earl AM, Hultgren SJ.

Sci Transl Med. 2017 Mar 22;9(382). pii: eaaf1283. doi: 10.1126/scitranslmed.aaf1283.

10.

One size doesn't fit all: unraveling the diversity of factors and interactions that drive E. coli urovirulence.

Schreiber HL 4th, Spaulding CN, Dodson KW, Livny J, Hultgren SJ.

Ann Transl Med. 2017 Jan;5(2):28. doi: 10.21037/atm.2016.12.73. No abstract available.

11.

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR, Schreiber H.

Cancer Immunol Res. 2017 Feb;5(2):127-136. doi: 10.1158/2326-6066.CIR-16-0293. Epub 2017 Jan 11.

12.

Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.

Zettl UK, Schreiber H, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; BETAPATH Study Group.

Acta Neurol Scand. 2017 Aug;136(2):116-121. doi: 10.1111/ane.12705. Epub 2016 Oct 30.

PMID:
27796033
13.

Antibody-Based Therapy for Enterococcal Catheter-Associated Urinary Tract Infections.

Flores-Mireles AL, Walker JN, Potretzke A, Schreiber HL 4th, Pinkner JS, Bauman TM, Park AM, Desai A, Hultgren SJ, Caparon MG.

MBio. 2016 Oct 25;7(5). pii: e01653-16. doi: 10.1128/mBio.01653-16.

14.

Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Binder DC, Arina A, Wen F, Tu T, Zhao M, Hoffman RM, Wainwright DA, Schreiber H.

Oncoimmunology. 2016 Feb 18;5(6):e1130207. doi: 10.1080/2162402X.2015.1130207. eCollection 2016 Jun.

15.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH.

Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.

16.

Tumor-associated fibroblasts predominantly come from local and not circulating precursors.

Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, Weichselbaum RR, Schreiber H.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7551-6. doi: 10.1073/pnas.1600363113. Epub 2016 Jun 17.

17.

Inducible targeting of cDCs and their subsets in vivo.

Loschko J, Rieke GJ, Schreiber HA, Meredith MM, Yao KH, Guermonprez P, Nussenzweig MC.

J Immunol Methods. 2016 Jul;434:32-8. doi: 10.1016/j.jim.2016.04.004. Epub 2016 Apr 9.

18.

Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation.

Loschko J, Schreiber HA, Rieke GJ, Esterházy D, Meredith MM, Pedicord VA, Yao KH, Caballero S, Pamer EG, Mucida D, Nussenzweig MC.

J Exp Med. 2016 Apr 4;213(4):517-34. doi: 10.1084/jem.20160062. Epub 2016 Mar 21.

19.

Fibrinogen Release and Deposition on Urinary Catheters Placed during Urological Procedures.

Flores-Mireles AL, Walker JN, Bauman TM, Potretzke AM, Schreiber HL 4th, Park AM, Pinkner JS, Caparon MG, Hultgren SJ, Desai A.

J Urol. 2016 Aug;196(2):416-421. doi: 10.1016/j.juro.2016.01.100. Epub 2016 Jan 28.

20.

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H.

Clin Cancer Res. 2016 Jun 1;22(11):2734-43. doi: 10.1158/1078-0432.CCR-15-2361. Epub 2015 Dec 14.

21.

Mycobacterium-Infected Dendritic Cells Disseminate Granulomatous Inflammation.

Harding JS, Rayasam A, Schreiber HA, Fabry Z, Sandor M.

Sci Rep. 2015 Oct 30;5:15248. doi: 10.1038/srep15248.

22.

Editorial overview: tumour immunology.

Schreiber H, Greenberg P.

Curr Opin Immunol. 2015 Apr;33:ix-xi. doi: 10.1016/j.coi.2015.03.006. Epub 2015 Mar 27. No abstract available.

PMID:
25823946
23.

Targeting cancer-specific mutations by T cell receptor gene therapy.

Blankenstein T, Leisegang M, Uckert W, Schreiber H.

Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Review.

24.

Is personality profile a relevant determinant of fatigue in multiple sclerosis?

Schreiber H, Lang M, Kiltz K, Lang C.

Front Neurol. 2015 Feb 4;6:2. doi: 10.3389/fneur.2015.00002. eCollection 2015. Review.

25.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

26.

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.

Freidel M, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M.

Acta Neurol Scand. 2015 Jan;131(1):9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11.

PMID:
25208898
27.

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.

Binder DC, Schreiber H.

Oncoimmunology. 2013 Dec 1;2(12):e26704. Epub 2013 Oct 22.

28.

Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin PC, Zal T, Schreiber H.

Oncoimmunology. 2013 Nov 1;2(11):e26677. Epub 2013 Nov 4.

29.

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Binder DC, Engels B, Arina A, Yu P, Slauch JM, Fu YX, Karrison T, Burnette B, Idel C, Zhao M, Hoffman RM, Munn DH, Rowley DA, Schreiber H.

Cancer Immunol Res. 2013 Aug;1(2):123-33. doi: 10.1158/2326-6066.CIR-13-0058.

30.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.

Binder DC, Schreiber H.

Cancer Res. 2014 Jan 15;74(2):632; discussion 635. doi: 10.1158/0008-5472.CAN-13-2216. Epub 2014 Jan 9. No abstract available.

31.

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H.

J Immunol. 2014 Feb 1;192(3):1286-93. doi: 10.4049/jimmunol.1202498. Epub 2013 Dec 23.

32.

Essential yet limited role for CCR2⁺ inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming.

Samstein M, Schreiber HA, Leiner IM, Susac B, Glickman MS, Pamer EG.

Elife. 2013 Nov 12;2:e01086. doi: 10.7554/eLife.01086.

33.

Innate and adaptive immune cells in the tumor microenvironment.

Gajewski TF, Schreiber H, Fu YX.

Nat Immunol. 2013 Oct;14(10):1014-22. doi: 10.1038/ni.2703. Review.

34.

Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium.

Schreiber HA, Loschko J, Karssemeijer RA, Escolano A, Meredith MM, Mucida D, Guermonprez P, Nussenzweig MC.

J Exp Med. 2013 Sep 23;210(10):2025-39. doi: 10.1084/jem.20130903. Epub 2013 Sep 16.

35.

From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections.

Silverman JA, Schreiber HL 4th, Hooton TM, Hultgren SJ.

Curr Urol Rep. 2013 Oct;14(5):448-56. doi: 10.1007/s11934-013-0354-5. Review.

36.

Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*.

Elmer J, Hou P, Wilcox SR, Chang Y, Schreiber H, Okechukwu I, Pontes-Neto O, Bajwa E, Hess DR, Avery L, Duran-Mendicuti MA, Camargo CA Jr, Greenberg SM, Rosand J, Pallin DJ, Goldstein JN.

Crit Care Med. 2013 Aug;41(8):1992-2001. doi: 10.1097/CCM.0b013e31828a3f4d.

37.

Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection.

Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, Darasse-Jèze G, Telerman SB, Breton G, Schreiber HA, Frias-Staheli N, Billerbeck E, Dorner M, Rice CM, Ploss A, Klein F, Swiecki M, Colonna M, Kamphorst AO, Meredith M, Niec R, Takacs C, Mikhail F, Hari A, Bosque D, Eisenreich T, Merad M, Shi Y, Ginhoux F, Rénia L, Urban BC, Nussenzweig MC.

Nat Med. 2013 Jun;19(6):730-8. doi: 10.1038/nm.3197. Epub 2013 May 19.

38.

IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner.

Liu RB, Engels B, Schreiber K, Ciszewski C, Schietinger A, Schreiber H, Jabri B.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8158-63. doi: 10.1073/pnas.1301022110. Epub 2013 May 1.

39.

ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation.

Sarkozy A, Hicks D, Hudson J, Laval SH, Barresi R, Hilton-Jones D, Deschauer M, Harris E, Rufibach L, Hwang E, Bashir R, Walter MC, Krause S, van den Bergh P, Illa I, Pénisson-Besnier I, De Waele L, Turnbull D, Guglieri M, Schrank B, Schoser B, Seeger J, Schreiber H, Gläser D, Eagle M, Bailey G, Walters R, Longman C, Norwood F, Winer J, Muntoni F, Hanna M, Roberts M, Bindoff LA, Brierley C, Cooper RG, Cottrell DA, Davies NP, Gibson A, Gorman GS, Hammans S, Jackson AP, Khan A, Lane R, McConville J, McEntagart M, Al-Memar A, Nixon J, Panicker J, Parton M, Petty R, Price CJ, Rakowicz W, Ray P, Schapira AH, Swingler R, Turner C, Wagner KR, Maddison P, Shaw PJ, Straub V, Bushby K, Lochmüller H.

Hum Mutat. 2013 Aug;34(8):1111-8. doi: 10.1002/humu.22342. Epub 2013 Jun 12.

PMID:
23606453
40.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H.

Cancer Cell. 2013 Apr 15;23(4):516-26. doi: 10.1016/j.ccr.2013.03.018.

41.

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.

Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, Müller-Reible C, Vorgerd M, Urban P, Schrank B, Deschauer M, Schlotter-Weigel B, Kohnen R, Lochmüller H.

Orphanet J Rare Dis. 2013 Feb 14;8:26. doi: 10.1186/1750-1172-8-26.

42.

[Epigenetic control of Th2 helper cell differentiation by the Suv39h1/HP1α pathway].

Zueva E, Allan RS, Cammas F, Schreiber HA, Masson V, Belz GT, Roche D, Maison C, Quivy JP, Almouzni G, Amigorena S.

Med Sci (Paris). 2012 Dec;28(12):1032-4. doi: 10.1051/medsci/20122812003. Epub 2012 Dec 21. French. No abstract available.

43.

Models of hemorrhagic shock: differences in the physiological and inflammatory response.

Pfeifer R, Lichte P, Schreiber H, Sellei RM, Dienstknecht T, Sadeghi C, Pape HC, Kobbe P.

Cytokine. 2013 Feb;61(2):585-90. doi: 10.1016/j.cyto.2012.10.022. Epub 2012 Nov 22.

PMID:
23178149
44.

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM.

Oncoimmunology. 2012 Sep 1;1(6):863-873.

45.

Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses.

Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, Kranz DM.

Gene Ther. 2013 Jun;20(6):634-44. doi: 10.1038/gt.2012.80. Epub 2012 Oct 11.

46.

Muscle MRI findings in limb girdle muscular dystrophy type 2L.

Sarkozy A, Deschauer M, Carlier RY, Schrank B, Seeger J, Walter MC, Schoser B, Reilich P, Leturq F, Radunovic A, Behin A, Laforet P, Eymard B, Schreiber H, Hicks D, Vaidya SS, Gläser D, Carlier PG, Bushby K, Lochmüller H, Straub V.

Neuromuscul Disord. 2012 Oct 1;22 Suppl 2:S122-9. doi: 10.1016/j.nmd.2012.05.012.

PMID:
22980763
47.

Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Stone JD, Chervin AS, Schreiber H, Kranz DM.

Biotechnol Prog. 2012 Nov-Dec;28(6):1588-97. doi: 10.1002/btpr.1631. Epub 2012 Oct 18.

48.

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM.

Cancer Immunol Immunother. 2013 Feb;62(2):359-69. doi: 10.1007/s00262-012-1336-z. Epub 2012 Aug 25.

49.

An epigenetic silencing pathway controlling T helper 2 cell lineage commitment.

Allan RS, Zueva E, Cammas F, Schreiber HA, Masson V, Belz GT, Roche D, Maison C, Quivy JP, Almouzni G, Amigorena S.

Nature. 2012 Jul 12;487(7406):249-53. doi: 10.1038/nature11173.

PMID:
22763435
50.

Inhalative vs. systemic IL-10 administration: differences in the systemic inflammatory response and end-organ inflammation following hemorrhagic shock.

Pfeifer R, Lichte P, Schreiber H, Sellei RM, Schmidt J, Dombroski D, Pape HC, Kobbe P.

Cytokine. 2012 Oct;60(1):266-70. doi: 10.1016/j.cyto.2012.05.028. Epub 2012 Jun 21.

PMID:
22727902

Supplemental Content

Loading ...
Support Center